- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
EC grants Marketing Authorisation for Obizur
13 November 2015 • Author: Victoria White
The European Commission (EC) has granted Marketing Authorisation for Baxalta’s Obizur for the treatment of bleeding episodes in adults patients with acquired haemophilia caused by antibodies to Factor VIII (FVIII).
Obizur is the first recombinant porcine sequence FVIII treatment available in Europe to treat acquired haemophilia A, and is designed to enable physicians to monitor treatment response by measuring FVIII activity levels in addition to clinical assessments.
“Gaining Marketing Authorisation for this first recombinant porcine option for acquired haemophilia in Europe reflects Baxalta’s commitment to improving patient lives,” said Brian Goff, executive vice president and president, Haematology, Baxalta. “We continue to build a broad, global portfolio of treatments that aim to reduce the burden of bleeding disorders for patients as we pursue a world without bleeds.”
Obizur approval based on results of a Phase II/III trial
The approval is supported by the positive results of a Phase II/III open-label trial that examined the efficacy and safety of Obizur in the treatment of serious bleeding episodes in adults with acquired haemophilia A. All patients treated with Obizur showed a positive response (bleeding stopped or reduced) and clinical improvement, with FVIII activity levels at 20% or higher at 24 hours after the initial infusion. Successful control of the initial bleeding episode was observed in 86% of all patients and in 94% of those treated with Obizur as the first-line treatment. The development of antibodies to porcine factor VIII was the only adverse reaction reported in more than five percent of patients.
OBIZUR is now approved in the United States, Canada and Europe, and is under regulatory review in Switzerland, Australia and Colombia.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics